Avalo Therapeutics (AVTX) Non Operating Income (2014 - 2026)
Avalo Therapeutics (AVTX) reported Non Operating Income of $1.3 million for Q1 2026, down 16.03% on a YoY basis from $1.5 million in Q1 2025, and up 124.86% quarter-over-quarter from -$5.2 million in Q4 2025.
Avalo Therapeutics (AVTX) Non Operating Income (2014 - 2026) Analysis & Trends
Avalo Therapeutics has reported Non Operating Income for 13 years, with the latest figure at $1.3 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 16.03% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$5.3 million (down 134.29% YoY), and the FY2025 full-year result was -$5.2 million, down 115.43% from the prior year.
- Non Operating Income for Q1 2026 stood at $1.3 million, up from -$5.2 million in the prior quarter.
- The five-year high for Non Operating Income was $35.9 million in Q3 2024, with the low at -$88.5 million in Q1 2024.
- Historically, Non Operating Income has averaged -$5.2 million across 5 years, with a median of -$26000.0 in 2023.
- The largest YoY upside for Non Operating Income was 211182.35% in 2024 against a maximum downside of 340346.15% in 2024.
- Avalo Therapeutics' Non Operating Income stood at -$949000.0 in 2022, then surged by 481.24% to $3.6 million in 2023, then slumped by 705.69% to -$21.9 million in 2024, then soared by 76.45% to -$5.2 million in 2025, then soared by 124.86% to $1.3 million in 2026.
- The last three Non Operating Income figures came in at $1.3 million (Q1 2026), -$5.2 million (Q4 2025), and -$3000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - | 1.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.28 Mn |
| Dec 31, 2025 | -5.16 Mn |
| Sep 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -1.43 Mn |
| Mar 31, 2025 | 1.53 Mn |
| Dec 31, 2024 | -21.91 Mn |
| Sep 30, 2024 | 35.88 Mn |
| Mar 31, 2024 | -88.52 Mn |
| Dec 31, 2023 | 3.62 Mn |
| Sep 30, 2023 | -17,000.00 |
| Mar 31, 2023 | -26,000.00 |
| Dec 31, 2022 | -949,000.00 |
| Sep 30, 2022 | -898,000.00 |
| Jun 30, 2022 | -1.15 Mn |
| Mar 31, 2022 | -20,000.00 |
| Sep 30, 2021 | -15,000.00 |
| Jun 30, 2021 | -5,000.00 |
| Dec 31, 2020 | 5.22 Mn |
| Sep 30, 2020 | 19,000.00 |
| Jun 30, 2020 | 398,000.00 |